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Variants of wild-type dengue serotype 2 (DEN-2) virus containing nucleotide substitutions at positions 14, 15, or 57 in the 5  NCR
wereconstructedbyPCR-mediatedsite-directedmutagenesis.Allthreevirusescontainingasinglepointsubstitutiondemonstrated
attenuation phenotype as evidenced by decreases replication and plaque size in cell culture assay. All three variants were less
neurovirulent in newborn mice compared to the wild type. The mutants were immunogenic in adult mice immunogenicity and
maintained stable replication characteristics following passage in mice. The variant viruses were competent for replication in
Aedes aegypi mosquito vector, albeit at lower levels of infection and dissemination in the mosquito than the wild-type Den-2
16681 virus. Although all of the viruses, including the wild type, were found transmissible in mosquito life cycles, they were found
subsequentially decreased in eﬃciency of infection, transmission, and dissemination rates along the mosquito generations and all
of them remained genetically stable.
1.Introduction
Dengue (DEN) viruses are ﬂaviviruses that cause dengue
fever (DF), dengue haemorrhagic fever (DHF), and dengue
shock syndrome (DSS) in humans and are transmitted
primarily by infected Aedes aegyptii or Aedes albopictus
mosquitoes. By immunological and genetic typing, DEN
viruses are divided into 4 serotypes including DEN-1, DEN-
2, DEN-3, and DEN-4. Secondary infection of humans with
a DEN serotype that diﬀers from the serotype of an initial
DEN infection often results in illness of greater severity.
This disease severity has been attributed to antibody depen-
dent enhancement and increased activation of chemokines.
Unsuccessful control of the mosquito vectors of DENs
has resulted in increased incidence of dengue disease in
several Southeast Asian countries, and the virus is currently
endemic in tropical regions worldwide. The optimal strategy
for preventing dengue disease appears to be vaccination.
However,thereiscurrentlynosafeandeﬀectiveDENvaccine
approvedforhumanuse,althoughanumberofDENvaccine
candidates are in preclinical development or in clinical trials.
Signiﬁcant obstacles to vaccine development include the
need to develop a tetravalent vaccine that protects recipients
against all four DEN serotypes, and the lack of a relevant
animal model for dengue pathogenesis.
The DEN viral genome is a single-stranded positive-
sense RNA molecule containing about 11,000 bases and is
organized as follows:5  noncoding region (5 -NCR),3 struc-
tural genes encoding capsid (C), premembrane/membrane
(prM/M) and envelope (E) proteins, 7 nonstructural (NS)
genes encoded for NS1, NS2A, NS2B, NS3, NS4A, NS4B, and
NS5 proteins, and 3  NCR. In the virus-infected cell, the 10
coding genes are translated from a single long open reading
frame into a polyprotein that is processed into the individual
proteins by both cellular and virus-speciﬁed enzymes. The
mechanisms of ﬂavivirus replication and translation have
been widely studied, and the involvement of both 5  and 3 
NCRs has been well documented [1–5]. Mutations in the 5 -
N C Ro fR N Av i r u s e ss u c ha sp o l i o v i r u s[ 6, 7], Venezuelan
equine encephalitis and Sindbis alphaviruses [8, 9], and2 Journal of Biomedicine and Biotechnology
the DEN-2 16681 virus [10, 11] have resulted in varying
degrees of attenuation of viral virulence. RNA secondary
structure in the 5 -NCR appears to be involved in viral
replication [12–14]. Mutations that disrupt base pairing
within complementary sequences at the 5  or 3  ends of DEN
genomic RNA can dramatically decrease RNA synthesis [12].
One of the DEN viruses that has been shown to have
potential as an eﬀective vaccine component of a tetravalent
DEN vaccine is the live-attenuated DEN-2 PDK-53 strain,
which has appeared to be safe and eﬀective in clinical trials
[15–17]. The PDK-53 virus exhibits a number of phenotypic
markers often associated with viral attenuation, including
small plaque size, decreased replication in mosquito cells,
temperature sensitivity, attenuation of neurovirulence in
suckling mice, and reduced viremia in monkeys compared
to the wild-type parental DEN-2 virus, strain 16681 [10].
The apparent attenuated phenotypic markers of the PDK-53
virus are encoded by a nucleotide mutation at position 57 in
the 5 NCR-57 and two other mutations that encode amino
acid changes at amino acid positions NS1-53 and NS3-250
[10]. These genetic markers of attenuation were identiﬁed by
utilizing infectious cDNA clones of the DEN-2 16681 virus
and its vaccine derivative, strain PDK-53 [10, 11]. The cDNA
clone of PDK-53 virus has been used to engineer chimeric
vaccine candidates that express the prM/E region of DEN-1,
DEN-3, and DEN-4 viruses, as well as West Nile virus, in the
attenuated genetic background of the DEN-2 PDK-53 virus.
These chimeric viruses were shown to retain the phenotypic
markers of the PDK-53 virus, relative to the wild-type DEN-
1, -3, and -4 viruses and West Nile virus [18–20].
Of the three genetic markers of DEN-2 PDK-53 atten-
uation, only the 5 -NCR-57 locus has shown a propensity
to revert to the wild-type residue [21]. In this study, we
constructed and characterized several variants of DEN-2
16681 virus that contained a single nucleotide substitution
in the 5  NCR to determine if other attenuating mutations
in this region could be identiﬁed and perhaps incorporated
into a second generation, PDK-53-based candidate vaccine.
We previously showed that a number of mutations in the
5 -NCR, particularly those involving deletions of bases,
were lethal. Here, we used the M-fold software [22], which
predicts RNA secondary structure, to engineer single point
mutations at genomic nucleotide positions 14, 15, and 57
that were predicted to have only minor eﬀect on the stem-
structure in the 5 -NCR. The variant viral phenotypes were
evaluated for possible markers of attenuation.
2.MaterialsandMethods
2.1. Construction of DEN-2 5 -NCR Mutants. The infectious
cDNA clone, designated pD2/IC-30P-A, of DEN2-16681
virus served as template for mutagenesis [11]. A small
subclone (plasmid pF1) containing the T7 promoter and
DEN genomic nucleotide positions 1–1380 was used as
template for PCR-mediated site-directed mutagenesis. Single
nucleotide substitutions in the 5 -NCR were performed by
designed primer pairs that contained the desired nucleotide
substitutionsatpositions14(CchangedtoA),15(Gchanged
to U), and 57 (C changed to U). PCR cycles were set at 94
◦C
for 15 sec, 50
◦Cf o r3 0s e c ,a n d7 2
◦C for 1min for 35 cycles.
PCR products were separated by electrophoresis in 0.8%
agarose gels (TBE buﬀer), then extracted from the agarose
and puriﬁed over spin columns. The puriﬁed cDNA from
PCR products was ligated into the appropriate restriction
enzyme sites of plasmid pF1, and the recombinant plasmid
was transformed into E. coli XL-1 Blue by electroporation.
The resulting variant pF1 plasmids were sequenced to
validate the presence of the desired mutation, and cDNA
cassettes containing designed mutations were reintegrated
between the SstI and SphI sites in the full-length pD2-
IC/30PAclone.Theligatedproductswereelectroporatedinto
E. coli XL-I Blue, and those infectious clone plasmids (pD2-
14.5 M,-15.5 M,and -57.5 M)containing the correctinserts
were ampliﬁed in, and extracted from, E. coli.
2.2. Transcription of Viral RNA and Derivation of Virus. In
vitro transcription of the XbaI-linearized infectious clone
plasmids was performed for 2h at 37
◦C by using the
Ampliscribe T7 transcription kit (EpiCentre Technologies)
and RNA cap structure analog 7mG (5 ) ppp (5 )A( N e w
England Biolabs). 200–500ng plasmid DNA was used for
each transcription reaction. The transcribed viral RNA was
transfected into LLC-MK2 cells (0.5mL containing 4–6 ×
106 cells/mL) by electroporation (Bio-Rad Gene Pulser). The
cells were shocked twice, then transferred to a 75cm2 ﬂask
in Dulbecco’s modiﬁed minimal essential medium (DMEM)
containing 10% fetal bovine serum (FBS) supplemented
with penicillin/streptomycin, and ﬁnally incubated in a
5% CO2 incubator at 37
◦C. Infection was evaluated by
the presence of cytopathic eﬀect (CPE) and DEN-speciﬁc
immunoﬂuorescence assay (IFA) after 7–10 days in culture.
The infectious medium was harvested and made in 20% in
FBS, clariﬁed by centrifugation, and the recombinant viruses
were in aliquots at −70
◦C.
2.3. Characterization of the Recombinant Viruses (D2-5 Ms)
2.3.1. Viral Replication in Cell Cultures and in Mosquitoes
Kinetic of Replication in LLC-MK2and in C6/36 Cells. LLC-
MK2 and C6/36 cells cultured in 75cm2 ﬂask were infected
at a multiplicity of infection (MOI) of 0.001PFU/cell with
DEN-2 16681 (wild type) or D2-5 M (D2-14.5 M, D2-
15.5 M, and D2-57.5 M) virus. Virus was adsorbed for 2h
to LLC-MK2 cells at 37
◦C and to C6/36 cells at 28–30
◦C.
Culture medium was changed to DMEM containing peni-
cillin/streptomycin and 5% FBS. Then, infected cells were
transferred to a 5%CO2 incubator at the appropriate tem-
perature for cells. Aliquots of culture medium were collected
at 48-h intervals to determine the viral titer. Viral replication
kinetics were determined by plaque titration assays in 6-well
plates containing conﬂuent monolayers of LLC-MK2 cells.
Mean plaque size diameter was determined for each virus by
measuring 20–40 plaques.
Kinetics of Replication in Aedes aegypti Mosquitoes. Female
Aedes aegypti mosquitoes were housed in cages at 30
◦ ±
2◦C, 80% humidity, and with a 12:12h light:dark period.Journal of Biomedicine and Biotechnology 3
They were reared with a normal rat chow diet and 10%
sucrose solution until infection. Mosquitoes were starved
1 day before being fed with a mixture of blood: DMEM
containing 106 PFU of virus: 10% sucrose in the ratio
0.5:1 .5:0 .5 until their stomachs became engorged. Two
hundred adult female mosquitoes were fed for each virus.
Six infected mosquitoes were randomly sampled at day 4–12
postinfection to determine the presence of viral infection by
IFA.
Determination of Viral Transmission and Dissemination.
Percent infection and dissemination rates were determine at
day 21 after oral infection. Virus-infected mosquitoes were
sampled (25 mosquitoes from each group) and killed by
freezing. Head and body portions were severed and squashed
on slides, which were treated with prechilled 90% acetone to
ﬁxed antigen. The slides were air dried at room temperature
and then analyzed by indirect IFA using the anti-DEN-E
protein-speciﬁc 3H5 monoclonal antibody. Positive IFA of
the body part indicated oral infection, and positive IFA of
head squashes indicated viral dissemination.
Standard Plaque Titration and Plaque Size Determinations.
Tenfold serial dilution series of the mutant viral seeds were
made in BA-1 diluent. Monolayers of LLC-MK2 cells were
inoculated with 0.2 mL of diluted virus, and adsorption
was performed for 1h at 37
◦C and 5% CO2.F o u rm L
of agarose overlay medium (2× nutrient solution and 2%
agarose solution, 1 : 1) was added, and after 7 days of
incubation the cultures were overlaid with 2mL of agarose
overlay medium containing 80ug/mL (diluted from 1%
stock) neutral red solution (Gibco) and reincubated in
the CO2 chamber. Plaques were quantiﬁed daily for 3-4
consecutive days. Plaque sizes were measured, and mean
plaque diameter was calculated from 20–40 plaques.
2.4. Temperature Sensitivity Phenotype. Two sets of LLC-
MK2 cell cultures in 25cm2 ﬂask were inoculated with virus
at MOI of 0.001PFU/cell, incubated for 2h at 37
◦C, and
then overlaid with 10mL of M199 medium containing 5%
FBS. One set of infected cells was incubated for 7–9 days in
5% CO2 at 37
◦C, the other set at 39
◦C. Culture media were
collected and analyzed to determine for viral titers.
2.5. Neurovirulence in Newborn Mice. Newborn white ICR
mice were infected intracranially with 104 PFU of virus in a
0.02mL volume. The animals were observed daily for signs
of paralysis and death. The body weights of surviving mice
were determined every week for 5 weeks.
2.6. Immunoprotection Assay and Viremia in Mice. Female
white ICR mice (3 wk-old, 9 mice per group) were injected
subcutaneously (s.c) with 105 PFU of virus. The animals
received two s.c. booster immunizations with the same viral
doseatday7andday21.Twoweeksafterthesecondboost,at
day 35, the mice were challenged intraperitoneally with 105
PFU of wild-type DEN-2 16681 virus. At day 5, 19, and 33,
mice were bled by orbital sinus venipuncture. The blood was
collected in nonheparinized capillary tubes, and the serum
was separated and kept frozen at −70
◦C.
The serum aliquots were tested for anti-DEN-2 neutral-
izing antibody by serum dilution-plaque reduction neutral-
ization test (PRNT50) without addition of exogenous com-
plement. In brief, twofold serial dilutions of heat-inactivated
serum (at 56
◦C, 30min) were incubated overnight at 4◦C
with an equal volume of diluent containing 60 PFU of
DEN-2 16681 virus. LLC-MK2 cells in 6-well plates were
inoculated with the serum-virus mixtures, then, incubated
for 90min at 37
◦C and 5% CO2. The plates were treated
as described for the plaque titration assay using the double
agarose overlay technique. Back titrations of the input wild-
type DEN-2 16681 virus were included in duplicate in the
assays. The neutralizing antibody titer was identiﬁed as the
highest serum dilution that reduced the number of input
plaques in the test by 50% or greater. The level of virus
circulating in the blood (viremia) was determined by the
plaque titration assay.
2.7. Ovarian Transmission of the Virus in 5 Generations of
Mosquito Cycle. Female mosquitoes that had been mated
with uninfected males were starved 1 day before feeding with
blood mixtures containing 106 PFU of virus. The female
mosquitoes (Generation 1, or G1) that hatched from eggs
from this initial mating were in turn mated, starved, and fed
virus-containing blood meals. This procedure was repeated
through G5, and adult females from each generation were
assayed for viral RNA and infectious viral titers. Percentage
of mosquito infection and dissemination was determined by
IFA of mosquitoes’ body and head tissues (50 mosquitoes
from each group).
2.8. Genetic Validation of the Mutants. After replication in
c e l lc u l t u r e sa n di nm o s q u i t o e s ,v i r a lg e n o m i cR N A sw e r e
extracted and either (a) reverse transcribed with RAV2-RT
using the 5  RACE (rapid ampliﬁcation of 5  cDNA ends)
kit(GIBCO,BRL)toobtain5 -terminalcDNAsequencingor
(b) subjected to RT-PCR using DEN-2-speciﬁc primer pairs
toamplifysegmentscoveringthecompletegenomeforwhole
genomic sequencing to verify the presence of the desired
mutation in the 5 -NCR and lack of spurious mutations in
the rest of the genome.
2.9. RNA Secondary Structure Analysis. Viral RNA secondary
structure analysis was performed by using the MFold
program version 3.1 created by Zuker [22].
3. Results
3.1. Viral Replication in Cell Cultures and in Mosquitoes
(Figure 1). In LLC-MK2 cells, variant viruses D2-14.5 M, -
15.5 M, and 57.5 M replicated to much lower peak titers of
6.8 ± 0.5, 6.9 ± 0.7, and 6.3 ± 0.5log10 PFU/mL, relative to
the peak 8.8 ± 0.7log10 PFU/mL titer of the wild-type 16681
virus(Figure 1(a)).InC6/36 cells,variant virusesD2-14.5 M
and -15.5 M also replicated to much lower peak titers (6.7
± 0.8, 6.2 ± 0.5log10 PFU/mL) than the 16681 virus (8.9 ±
1.1log10 PFU/mL; see Figure 1(b)). However the D2-57.5 M
variant replicated to a peak titer of 8.9 ± 1.1log10 PFU/mL
that was equivalent to the peak titer of 16681 virus in C6/364 Journal of Biomedicine and Biotechnology
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Figure 1: Kinetic of replication of DEN-2 mutants in LLC-MK2
cells (a), C6/36 cells (b), and mosquitoes (c).
cells. The latter result contrasts with the results of Butrapet
[10], who reported that the 5 NCR-57 mutant replicated to
signiﬁcantly lower levels than 16681 virus in C6/36 cells. The
kinetics of replication of all 3 mutants, particularly the D2-
15.5 M mutant, were decreased in Aedes aegypti mosquitoes
(Figure 1(c)). At day 21, the titer of the D2-57.5 Mv i r u s
approached that of wild-type virus, while the titers of D2-
15.5 M and -14.5 Mr e m a i n e dd e p r e s s e d( Figure 1(c)).
However,theplaquesizes ofD2-14.5 M(1.17 ±0.02mm
mean plaque diameter), D2-15.5 M (1.16 ± 0.02mm), and
D2-57.5 M (1.49 ± 0.06mm) were statistically signiﬁcantly
(P<. 0001) smaller from the plaque size of the 16681 virus
(1.99 ± 0.07mm) (data not shown). These relative plaque
sizes of these four viruses were maintained following passage
of the viruses in C6/36 cells and Aedes aegypti mosquitoes
(not shown).
3.2. Neurovirulence in Newborn Mice. Newborn ICR mice
were challenged intracranially with each of the four viruses
in two separate experiments (16 mice each) (Table 1). The
wild-type 16681 virus caused 100% fatality. Virus variants
Table 1: Neurovirulence Assay of DEN-2 mutants in new born
mice.
Viruses Neurovirulence
%m o r t a l i t y( n) Average survival time
(AST) (days ± SD)
D2-16681 100 (32) 4.7 ± 0.32
D2-14.5 M 32.5 (32) 16.9 ± 0.67
D2-15.5 M 31 (32) 8.6 ± 0.61
D2-57.5 M 31 (36) 17.9 ± 0.68
Table 2: Temperature sensitivity (ts) phenotype in LLC-MK2 cell
and percent of oral infection and dissemination in Aedes aegypti
mosquitoes.
Viruses ts phenotype
(EOP ratio)
Positive IFA head/body
(% dissemination)
n = 25
D2-16681 1.3 19/24 (79%)
D2-14.5
 M 1.7 11/20 (55%)
D2-15.5
 M 1.2 7/16 (44%)
D2-57.5
 M 1.6 8/19 (42%)
D2-14.5 M, -15.5 M, and -57.5 M all resulted in 31%–
32.5% mortality. The average survival times (ASTs) of mice
challenged with D2-14.5 M, D2-15.5 M, and D2-57.5 M,
and which suﬀered mortality, were statistically signiﬁcantly
greater than the AST of mice challenged with the 16681 virus
(P<. 0001). Excluding the animals which suﬀered mortality,
the weekly incremental increases in mean body weights were
similar for each experimental group during the experimental
period.
3.3. Temperature Sensitivity Phenotype in LLC-MK2 Cells
and Percent Infection and Dissemination in Aedes aegypti
Mosquitoes. The wild-type 16681 virus, as well as all three
of the variant viruses, was not temperature sensitive when
replicated in LLC-MK2 cells. The 16681 and D2-15.5 M
viruses showed similar 37
◦C-titer/39
◦C-titer ratios of 1.3
and 1.2, respectively, while the D2-14.5 M and D2-57.5 M
variants had ratios of 1.7 and 1.6, respectively.
The viral competency of each virus in Aedes aegypti
mosquitoes was also examined. Adult female mosquitoes
were fed blood meals containing virus. The presence of
virus in the mosquitoes was assayed by IFA at 21 days
after feeding. Positive IFA detection in mosquitoes’ bodies
indicated susceptibility to viral infection. Nearly all (96%)
of the tested mosquitoes became infected with the wild-type
16681 virus; whereas the three variant viruses resulted in 64–
80% positive infection rate (Table 2). Positive IFA detection
in mosquitoes’ heads indicated viral dissemination from the
midgutandthepotentialfortransmissionofthevirus.Ofthe
25 mosquitoes tested in each virus group, the three variant
viruses exhibited much reduced rates of dissemination to
the head, 42%–55%, than did the wild-type 16681 virus
(79%).Journal of Biomedicine and Biotechnology 5
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Figure 2: Kinetic of viremia of DEN-2 mutants in mice at day of
immunized (a), boost 1st (b), and boost 2nd (c).
3.4.ImmunoprotectionAssayandLevelofViremiainMice. To
determine whether the mutant viruses could be maintained
in the blood circulation and be able to boost mice immune
response, the blood taken from immunized mice were
titered for replication kinetic. The mutant viruses exhibited
signiﬁcantly lower replication eﬃciency than the wild type
(Figure 2). The viremia titers of D2-5 M were signiﬁcant
diﬀerence from D2-16681 viruses (P = .002–.0001). The
plaque phenotypes of all the viruses were not signiﬁcantly
changed from the primary derived viruses (data not shown).
The neutralizing antibody production from immunized
mice with D2-16681and D2-5 M determined at day 5,
19, 33, and 38 by PRNT50 assay showed some extent of
inducing immunogenic response. Obviously, the mutant
viruses induced 2–8 folds less titers than the wild type
(Table 3).
Viral Transmission in Aedes aegypti mosquitoes
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Figure 3: Viral transmission and titers in each generation.
3.5. Viral Transmission in Aedes aegypti Mosquitoes and
Genetic Validation of the Mutants. To determine the repli-
cation phenotype of virus in the mosquito progeny, viruses
were isolated from ovarian transmitted mosquitoes at 1–5
generations. The result indicated that the viruses isolated
from mosquitoes infected with D2-5 M and D2-16681
maintained their growth and replication characteristics,
in which D2-5 M viruses were lower eﬃcient than D2-
16681(Figure 3).Thepercentofinfectionanddissemination
rate were also reduced (Table 4). Furthermore, full-length
nucleotide sequencing analysis of the virus before mosquito
ingestion and after 5 generations of vector transmission
indicated stable RNA sequences of the viral gene (data not
showed).
3.6. Viral RNA Secondary Structure Analysis. Substitution
mutation at nucleotide position 14, 15, and 57 in 5  NCR of
D2 gene caused mild alteration of RNA secondary structure
from that of the wild type (Figure 4(a)). At the stem-2
and loop-2 region, D2-14.5 M showed a small splitting
stem (Figure 4(b)), D2-15.5 M showed shortening stem and
widening loop (Figure 4(c)), while D2-57.5 M maintained a
similar pattern to the wild type (Figure 4(d)).
4. Conclusion and Discussion
The recombinant viruses that carried a single point sub-
stitution in the conserved 5 NCR gene of DEN-2 were
genetically stable in the Aedes aegypti mosquito vector and
in mice. The variant viruses exhibited decreased repli-
cation eﬃciency in LLC-MK2 and, except for the D2-
57.5 M virus which replicated as well as the 16681 virus,
in C6/36 cells as well. All three variants had decreased
replication proﬁles in Aedes aegypti mosquitoes. These three
v i r u s e sp r o d u c e ds m a l l e rp l a q u ea n dw e r el e s sv i r u l e n t
in newborn mice compared to the wild-type virus. An
independently engineered variant at 5 NCR-57 also exhib-
ited similar small plaque size and decreased neurovirulence
level for newborn mice, but diﬀered from the D2-57.5 M6 Journal of Biomedicine and Biotechnology
Table 3: Immunoprotection assay of DEN-2 mutants.
PRNT titer against D2-16681 virus in pooled sera
Viruses Immunized (day 5th) Boost 1 (day 19th) Boost 2 (day 33rd) Challenged (day 38th)
D2-16681 160 640 1280 5120
D2-14.5 M 20 80 160 640
D2-15.5 M 80 160 160 1280
D2-57.5 M 40 160 320 2560
Table 4: Percent Infection and Dissemination in generation 1–5.
Viruses D2-16681 D2-14.5
 M D2-15.5
 M D2-57.5
 M
Infection
(%)
a
Dissemination
(%)
b
Infection
(%)
Dissemination
(%)
Infection
(%)
Dissemination
(%)
Infection
(%)
Dissemination
(%)
G1 31 (62%) 24 (77%) 19 (38%) 10 (53%) 21 (42%) 12 (57%) 16 (32%) 7 (44%)
G2 42 (48%) 20 (47%) 16 (32%) 5 (31%) 23 (46%) 10 (43%) 15 (30%) 5 (33%)
G3 37 (74%) 15 (40%) 18 (36%) 7 (39%) 17 (34%) 5 (29%) 5 (10%) 3 (60%)
G4 20 (40%) 14 (70%) 16 (32%) 7 (44%) 19 (38%) 5 (26%) 9 (18%) 1 (11%)
G5 18 (36%) 6 (33%) 12 (24%) 4 (33%) 8 (16%) 3 (38%) 4 (8%) 2 (50%)
anumber of IFA positive mosquitoes in gut part/number of mosquitoes (n = 50) ×100.
bnumber of IFA positive mosquitoes in head part/number of IFA positive mosquitoes in gut part × 100.
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Figure 4: Predicted RNA secondary (stems and loops) structure of 5 NCR of DEN2-16681 (stem1 = bases 3–9 and 64–71, stem2 = bases
11–16 and 56–61). The arrow represented the mutation position.Journal of Biomedicine and Biotechnology 7
results reported here in having a decreased replication
proﬁle in C6/36 cells [10]. We are presently unable to
explain the discrepancy in the C6/36 replication proﬁles
between the D2-5 M virus and the 5 NCR-57 virus reported
previously.
Based on the modiﬁed in vitro and in vivo phenotypes
of the variant viruses, these viruses were considered to have
vaccine potential. Mice immunized with three high doses
(105 pfu each) of each of the variant viruses developed
signiﬁcant levels of neutralizing antibodies and challenging
with DEN2-16681. The mice infection with DEN2-16681
anditsderivedmutants,however,demonstratedsomedegree
of neurovirulence including paralysis and weakness after
38 days and at least 1 mouse from each group died
during the assay. Although involving only a minor alteration
in the 5 NCR predicted RNA secondary structure [22],
the single base-substitution mutations at 5 NCR positions
14, 15, and 57 resulted in signiﬁcant alterations in in
vitro and in vivo viral. A single nucleotide substitution at
position 69 of the American DEN-2 genotype, leading to
a minor change (shortening) of stem-1, has been shown
to encode a low-virulence genotype [23]. In our previous
study, we were unable to derive infectious viruses from
multiple-site (>2 nucleotides) substitutions between 5 NCR
positions 56–61 of the [24]. The present study provides
further evidence for the potential biological signiﬁcance
of single nucleotide substitutions that cause apparently
minor perturbations in RNA secondary structure in the
5 NCR. Characterization of the mutants in Aedes aegypti
mosquito suggested that they were competent for replication
in this vector. Although both DEN-2 wild type and the
D2-5 M viruses were capable of vertical transmission in
Aedes aegypti, the mutants’ growth and replication in
infected mosquitoes and the progenies were less eﬃcient
than those of the wild type. The rates of viral infection
and dissemination were signiﬁcantly decreased after 5 gen-
erations of mosquito life cycle. The lower transmission and
dissemination in the mosquito suggested the poorer potency
of the mutants to be transmitted to human host. DEN2-
16681 wild-type and the derived D2-5 M viruses remained
genetically stable in the vector even after passage for
5 generations.
In conclusion, the D2-14.5 M and D2-15.5 M variant
viruses exhibited in vitro and in vivo phenotypic markers
of attenuation that were similar to many of the markers
reported earlier for the 5 NCR-57 mutation [10]. The
5 NCR-57 C(wild-type)-to-T(vaccine candidate) mutation
is one of the three dominant mutations that have been
reported to encode the attenuated phenotype of the can-
didate DEN-2 PDK-53 vaccine virus [10]. The D2-57.5 M
mutation has been shown to have a propensity to revert
to the wild-type C residue upon serial passage in Vero
cell culture [21]. Incorporation of one or both D2-14.5 M
and D2-15.5 M mutations together with the D2-57.5 M
mutation may lead to a more stable attenuation locus
in the 5 NCR of the DEN-2 viral genome. The single-
point mutants appeared to retain their plaque size and
replicationphenotypesfollowingpassageinmiceandvertical
transmission in mosquitoes.
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